Literature DB >> 28787411

First new drug approval for AML in 15 years.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28787411     DOI： 10.1038/nbt0817-696

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

2.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.

Authors:  Ken-Hong Lim; Ayalew Tefferi; Terra L Lasho; Christy Finke; Mrinal Patnaik; Joseph H Butterfield; Rebecca F McClure; Chin-Yang Li; Animesh Pardanani
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

3.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

Authors:  Jason Gotlib; Hanneke C Kluin-Nelemans; Tracy I George; Cem Akin; Karl Sotlar; Olivier Hermine; Farrukh T Awan; Elizabeth Hexner; Michael J Mauro; David W Sternberg; Matthieu Villeneuve; Alice Huntsman Labed; Eric J Stanek; Karin Hartmann; Hans-Peter Horny; Peter Valent; Andreas Reiter
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

4.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

5.  Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug.

Authors:  Jacob M Rowe; Bob Löwenberg
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

6.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962
  6 in total
  4 in total

1.  Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.

Authors:  Jinzhu Chen; Juan Feng; Zhihong Fang; Jing Ye; Qinwei Chen; Qiuling Chen; Kai Chen; Xiaoming Xiong; Guowei Li; Haihan Song; Bing Xu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Thymoquinone Suppresses Cell Proliferation and Enhances Apoptosis of HL60 Leukemia Cells through Re-Expression of JAK/STAT Negative Regulators.

Authors:  Belal Almajali; Hamid Ali Nagi Al-Jamal; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abd Almonem Doolaanea; Wisam Nabeel Ibrahim; Syed Ahmad Tajudin
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

3.  Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.

Authors:  Jing Ye; Jie Zha; Yuanfei Shi; Yin Li; Delin Yuan; Qinwei Chen; Fusheng Lin; Zhihong Fang; Yong Yu; Yun Dai; Bing Xu
Journal:  Clin Epigenetics       Date:  2019-10-07       Impact factor: 6.551

4.  Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.

Authors:  Kazuhiro Katayama; Kohji Noguchi; Yoshikazu Sugimoto
Journal:  Oncotarget       Date:  2018-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.